Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (302)	5/8/2000 7:47:00 PM
From: allen menglin chen	Read Replies (1) \| Respond to of 746

DoubleTwist can claim patents on 60% of human genes, if they actually have done their "discoveries". I cannot find the very fishy pts in DT's PRs yet -- probably I haven't followed them long enough. All genomic companies are claiming their credits these days, including CRA :) If DT has done almost all the gene works, how can we long GNSL or CRA for long term?! W/o any indepth bio background, how can u manage to read all those CRA and bio related news -- must be $$$!